Short Talks Selected from Proffered Abstracts

PR-01 Stable subclones and acquired genomic events present after treatment of HGSC. Jaana Oikkonen. University of Helsinki, Helsinki, Finland.


PR-03 Half of CCNE1-amplified high-grade serous ovarian carcinomas are homologous recombination deficient and platinum-sensitive. Liisa Kauppi. University of Helsinki, Helsinki, Finland.


PR-05 ZNFX1 is a Master Regulator for Epigenetic Reprograming of Mitochondrial Inflammasome Signaling and Pathogen Mimicry in Cancer Cells. Lora Stojanovic. Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, United States.

PR-06 A novel bispecific NK cell engager targeting FSHR and Siglec-7 displays potent anti-tumor immunity against ovarian cancer. Devivasha Bordoloi. The Wistar Institute, Philadelphia, United States.

PR-07 Patient-derived immunocompetent cultures reveal personalized immunotherapies and new treatment options for therapy resistant patients with high-grade serous ovarian cancer. Anniina Färkkilä. University of Helsinki, Helsinki, Finland.

PR-08 Follicular fluid aids in cell adhesion, spreading and shows an age-dependent effect on DNA damage in fallopian tube epithelial cells. Amrita Salvi. University of Illinois, Chicago, Chicago, United States.


PR-10 Dual targeting of IDO1/TDO2 inhibits tumor progression and attenuates the immune suppressive tumor microenvironment. Benjamin Bitler. The University of Colorado, Denver, United States.

PR-11 Role of cancer associated fibroblasts in ovarian cancer relapse. Argha Ghosh. Indiana University School of Medicine - Bloomington, Bloomington, United States.
PR-12 Proteogenomic Analysis of Enriched Tumor Epithelium Identifies Prognostic Signatures and an Increased Dependency of Homologous Recombination Proficient Cells on BMI1 in High Grade Serous Ovarian Cancer. Thomas Conrads. Inova Health System, Falls Church, United States.
Patient Advocacy


A002 Collaboration Between the Physician/Researcher and Patient/Survivor is KEY. Deborah Binder. Patient Advocate, Edmonds, WA, United States.

Epigenetics and Epitranscriptomics


A004 Patterns of IncRNA-regulated gene expression in high-grade serous ovarian carcinomas. Brett Reid. Moffitt Cancer Center, Tampa, FL, United States.

A005 Alanine metabolism is a ARID1A-dependent vulnerability in clear cell ovarian carcinoma. Hao Nie. MD Anderson Cancer Center, Houston, TX, United States.


A007 DNA methylation analysis comparing high-grade serous ovarian cancer to the normal ovary with adjustment for cell type variation identifies tumor-specific methylation alterations. Irma Vlasac. Geisel School of Medicine, Lebanon, NH, United States.

A008 Characterizing the role of somatic and constitutional methylation in ovarian cancer. Isabel Rodriguez. University of Washington, Seattle, WA, United States.

Drug Discovery, Development, and Novel Pathways

A009 A novel bispecific NK cell engager targeting FSHR and Siglec-7 displays potent anti-tumor immunity against ovarian cancer. Devivasha Bordoloi. The Wistar Institute, Philadelphia, PA, United States.

A010 Targeting the nucleoli as a strategy to treat ovarian cancer. Elaine Sanij. St Vincent’s Institute of Medical Research, Fitzroy, VIC, United States.

A011 An implantable microdevice to interrogate responses to therapy in ovarian cancer. Elizabeth Stover. Dana-Farber Cancer Institute, Boston, MA, United States.

A012 Dual-selective inhibitors of PKMYT1 and WEE1 for improved potency and therapeutic profile. Evan Chiswick. Psivant Therapeutics, Boston, MA, United States.
A013 Auranofin induces lethality driven by reactive oxygen species in high-grade serous ovarian cancer cells. Farah Abdalbari. McGill University, Montreal, QC, Canada.

A014 A valid second line therapy for high grade serous ovarian cancer. Flavio Rizzolio. Ca' Foscari University of Venice, Venezia, Italy.

A015 Glutaminase inhibitor induces Chk1-inhibitor induced replication stress and synergistically kills chemo-resistant and GLS ovarian cancer cells. Ganesh Acharya. Texas Tech University Health Sciences Center, Lubbock, TX, United States.

A016 Organotypic High-throughput Screening Identifies the Combinatorial Treatment of Navitoclax and YM155 that Target Chemoresistant Ovarian Cancer Cells. Hilary Kenny. University of Chicago, Chicago, IL, United States.


A018 CASC4/GOLM2 drives high grade serous ovarian cancer anoikis resistance through recycling of EGFR. Jaidev Bapat. University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

A019 Development of adaptive anoikis resistance promotes ovarian cancer metastasis that can be prevented by CDK8/19 Mediator kinase inhibition. Karthikeyan Mythreye. University of Alabama, Birmingham, AL, United States.

A020 NAD+ Boosting through NRH supplementation enhances treatment efficacy in EOC. Kevin Lee. USA Health Mitchell Cancer Institute, Mobile, AL, United States.

A021 The beta-arrestin1/endothelin axis bolsters a CAF-dependent invadosome activity and ovarian cancer metastatic potential. Laura Rosanò. Institute of Biology and Molecular Pathology (IBPM)-CNR, Rome, Italy.

A022 ZNFX1 is a Master Regulator for Epigenetic Reprograming of Mitochondrial Inflammasome Signaling and Pathogen Mimicry in Cancer Cells. Lora Stojanovic. Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, United States.

A023 Pre-clinical evaluation of the gamma-secretase inhibitor nirogacestat in an adult-type ovarian granulosa cell tumor model. Maeva Chauvin. Massachusetts general hospitral / Harvard medical school, Boston, MA, United States.
A024 High throughput screen for identifying inducers of Autophagic Cell Death in Ovarian Carcinoma. Pahul Hanjra. MD Anderson Cancer Center, Houston, TX, United States.


A026 Identifying mechanisms to target in combination with trametinib to improve therapeutic efficacy in low-grade serous ovarian cancer. Rebekah Peplinski. University of Iowa, Iowa City, IA, United States.

A027 Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma. Sampsa Hautaniemi. University of Helsinki/Faculty of Medicine/ONCOSYS, Helsinki, Finland.

A028 Investigating the role of SOX2 in promoting anchorage-independent survival of ovarian cancer cells. Shriya Kamlapurkar. University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

A029 Development of a new iPSC-derived organoid platform to model FTE-derived HGSOC onset and progression. Simone Roverselli. European Institute of Oncology, Milan, Italy.

A030 Regulation of SIRT3 overexpression in Anchorage Independent Ovarian Cancer. Sneha Srinivasan. University of Pittsburgh School of Medicine, Pittsburgh, AZ, United States.

A031 Causal determinants of drug-resistance in patients with High-Grade Serous Ovarian Carcinoma from multi-site single cell RNA sequencing data. Sohrab Salehi. Memorial Sloan Kettering Cancer Center, New York, NY, United States.

A032 The role of ASIC2 and calcium influx in epithelial ovarian cancer pathogenesis. Tanvi Joshi. USA Health Mitchell Cancer Institute, Mobile, AL, United States.

A033 The transcriptional landscape of cisplatin resistance and its relationship with epithelial mesenchymal transition in ovarian cancer. Tise Suzuki. Loma Linda University, Loma Linda, CA, United States.

A034 Combination of ATR inhibitor (ATRI) and AKT inhibitor (AKTi) reduces tumor growth and prolongs survival in BRCA2 mutant (BRCA2m) PARP inhibitor (PARPi)-resistant high-grade serous ovarian cancer (HGSC). Tzu-Ting Huang. National Cancer Institute, Bethesda, MD, United States.


American Association for Cancer Research Special Conference:
OVARIAN CANCER  | October 5-7, 2023| Westin Seaport Boston | Boston, MA

A037 Exploring the therapeutic effectiveness of EO3001 in the treatment of clear cell ovarian cancers with ARID1A mutations. Yuchen Ding. The University of British Columbia, BC Cancer Research Institute, Vancouver, BC, United States.

A038 Epigenetic compound library screen of ovarian clear cell carcinoma cell line models identifies decreased cell viability following treatment with the Bruton tyrosine kinase inhibitor ibrutinib. Yue Ma. University of Technology Sydney, Haymarket, NSW, United States.

A039 SRMS confers platinum resistance in ovarian cancer through weakening MKK4-JNK-mediated apoptosis response. Yunhan Jiang. UT Health Science Center at San Antonio, San Antonio, TX, United States.

Early Detection and Prevention


A041 Low-dose aspirin use and risk of ovarian cancer: A combined analysis from two nationwide studies in Denmark and Sweden. Guoqiao Zheng. Danish Cancer Society Research Center, Copenhagen, Denmark.

A042 History of infertility and risk of ovarian cancer in the Women’s Health Initiative. Holly Harris. Fred Hutchinson Cancer Center, Seattle, WA, United States.

A043 Role of stromal CD10 expression in modulating the immune microenvironment of ovarian clear cell carcinoma. Huda Atiya. University of Pittsburgh, Pittsburgh, PA, United States.

A044 Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer. Jae-Hoon Kim. Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

A045 Improving the diagnostic accuracy of an ovarian cancer triage test using a joint miRNA-protein model. James Webber. Brigham and Women's Hospital, Boston, MA, United States.

A046 Metabolomic profiles associated with breastfeeding and subsequent ovarian cancer risk. Jennifer Mongiovi. Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital, Boston, MA, United States.


A049 Fallopian tubes of BRCA carriers are characterized by an alteration of epithelial differentiation. Quentin Chartreux. Cedars-Sinai Medical Center, Los Angeles, CA, United States.


A051 Prior chlamydial infection and ovarian cancer risk by tumor p53 expression. Sarina Pollat. University of Utah, Salt Lake City, UT, United States.

A052 ROS in ovulatory follicular fluid exert de novo mutagenic activities through activation-induced cytidine deaminase acting on the TP53 gene in the fallopian tube epithelial cell. Tang-Yuan Chu. Tzu Chi Medical Center, Hualien, Taiwan.

A053 Understanding Geospatial Relationships in Ovarian Cancer Risk. Victoria Wang. Brigham and Women's Hospital, Boston, MA, United States.

A054 The evolution of ovarian high grade serous carcinoma from STIC lesions. Zhao Cheng. Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

Other
A055 Association between Pre-diagnosis Diet Quality and Ovarian Cancer Risk and Survival in the NIH-AARP Diet and Health Study. Anlan Cao. Yale School of Public Health, New Haven, CT, United States.


A057 Inter-tumor heterogeneity revealed by multi-site whole genome sequencing of high grade serous ovarian cancer. Elizabeth Christie. Peter MacCallum Cancer Centre, Melbourne, Australia.

A058 Mesenchymal stem cells act as a selective pressure for High Grade Serous Ovarian Cancer initiation. Geyon Garcia. University of Pittsburgh, Pittsburgh, PA, United States.

A059 Stable subclones and acquired genomic events present after treatment of HGSC. Jaana Oikkonen. University of Helsinki, Helsinki, Finland.
A060 **Half of CCNE1-amplified high-grade serous ovarian carcinomas are homologous recombination deficient and platinum-sensitive.** Liisa Kauppi. University of Helsinki, Helsinki, Finland.

A061 **Detection and dynamic monitoring of clonal hematopoiesis mutations in women receiving systemic therapies for high grade serous ovarian carcinoma.** Rebecca Porter. Dana-Farber Cancer Institute, Boston, MA, United States.

A062 **Untargeted analysis of plasma tumor fraction is an independent prognostic marker of response to front line chemotherapy in High-Grade Serous Epithelial Ovarian Cancer: the MITO-16A/MANGO-OV2A;clinical trial experience.** Sergio Marchini. HUmanitas Research Hospital, Rozzano, Italy.

**Rare Ovarian Tumors**

A063 **What can we learn from a retrospective evaluation of HER2, P53 and P16 INK4A protein expression in rare ovarian tumors.** Kavitha Advikolanu-Rao. TDR Services LLC., Bridgewater, NJ, United States.

A064 **Study of molecular pathways involved in the development of ovarian cancer brain metastases.** Korina Mouzakitis. Université de Sherbrooke, Sherbrooke, QC, Canada.

A065 **High throughput drug screening to decipher the mechanisms of trametinib adaptive resistance in low-grade serous ovarian cancer cell lines.** Kwong-Kwok Wong. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A066 **The Cytotoxic effects of Oxaliplatin and 5-Fluorouracil against Low-Grade Serous Ovarian Cancer Cells.** Rewati Prakash. McGill University, Montreal, QC, Canada.

A067 **A novel genetically engineered mouse model of ovarian carcinosarcoma.** Ruth Perets. Rambam Health Care Campus and Technion - Israel Institute of Technology, Haifa, Israel.

A068 **Dual multiplexing analysis of the tumor immune microenvironment of rare ovarian granulosa cell tumors identified predictors of recurrence and potential therapeutic targets.** Tyvette Hilliard. University of Notre Dame, South Bend, IN, United States.

**Tumor Microenvironment and Immune Oncology II**

A069 **High-resolution volumetric imaging of primary and metastatic high-grade serous ovarian cancer explants.** Adele Connor. University College Dublin, Dublin, Ireland.

A070 **Adoptive transfer of BiTE-secreting T cells combined with immune checkpoint blockade can elicit divergent cellular changes in the ovarian tumor microenvironment resulting in variable therapeutic responses.** AJ McGray. Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
A071 **TGF-β1/2 signaling in ovarian cancer is dependent on betaglycan ectodomain shedding that occurs in a heparan sulfate and TIMP3-dependent manner.** Alex Choi. UAB, Birmingham, AL, United States.

A072 **Altering the Ovarian Cancer Tumor Microenvironment Using CAR T Cell Therapy.** Alexandra McMellen. University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

A073 **Patient-derived immunocompetent cultures reveal personalized immunotherapies and new treatment options for therapy resistant patients with high-grade serous ovarian cancer.** Anniina Färkkilä. University of Helsinki, Helsinki, Finland.

A074 **Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1/2 PESCO Trial.** Ana Veneziani. Princess Margaret Cancer Centre, Toronto, ON, Canada.

A075 **Stromal cell DDR2 promotes ovarian cancer metastasis.** Angela Schab. Washington University in St. Louis, St. Louis, MO, United States.

A076 **T-cell exhaustion is an independent predictive biomarker of clinical outcome in high grade serous ovarian cancer regardless of homologous recombination deficiency status.** Anna Salvioni. University Cancer Institute of Toulouse-Oncopole and Cancer Research Center of Toulouse, Toulouse, France.

A077 **The utility of surgical minimal residual disease after frontline treatment for prognostic and investigational opportunities in advanced ovarian cancer.** Anne Knisely. University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A078 **In vivo tumor micro-environment characterization: preliminary results of an ovarian cancer patients-derived co-culture organoids platform.** Floriana Camarda. Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

A079 **G-CSF released from ovulation recruits and activates neutrophils in the peritoneum to aid transformation, seeding, and invasion of high-grade serous carcinoma.** Hsuan Shun Huang. Center for Prevention and Therapy of Gynecological Cancers, Department of Research, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.

A080 **CD8+T-cell Interplay with Myeloid Cells as Spatial Determinant of Chemotherapy Response in the Tumor Microenvironment of Metastatic High-grade Serous Ovarian Cancer.** Inga-Maria Launonen. University of Helsinki, Helsinki, Finland.

A081 **Chromobox 2 (CBX2) drives an immunosuppressive tumor microenvironment in high grade serous carcinoma (HGSC).** Lindsay Brubaker. University of Colorado, Denver, CO, United States.
A082 Targeting sterol regulatory element binding protein 1 (SREBP1) improves response to standard-of-care chemotherapy; and alters the tumor microenvironment in pre-clinical models of obesity and ovarian cancer. M. Sharon Stack. University of Notre Dame Harper Cancer Research Institute, South Bend, IN, United States.

A083 Personalized targeted circulating tumor DNA (ctDNA) and T-cell responses after combined neoantigen vaccine and immune checkpoint blockade in ovarian cancer. MacLean Selleris. Dana Farber Cancer Institute/Harvard Cancer Center, Boston, MA, United States.

A084 AMH paracrine signaling between cancer and mesothelial cells modulates the ovarian tumor immune microenvironment. Maeva Chauvin. Massachusetts General Hospital, Boston, MA, United States.

A085 Evaluating the Immune Modulating Effects of Standard Chemotherapies and Macrophage-Targeted Therapy in a Humanized Patient-Derive Xenograft Model of High Grade Ovarian Cancer. Mara Steinkamp. University of New Mexico School of Medicine, Albuquerque, NM, United States.

A086 Rapid expansion of natural, MUC1-activated T cells from the peripheral blood of ovarian cancer patients for adoptive cell therapy. Marion Curtis. Mayo Clinic, Scottsdale, AZ, United States.

A087 An ovarian cancer scRNA-seq atlas to dissect tumor-host interactions underlying metastatization and chemoresistance. Marta Sallese. European Institute of Oncology, Milan, MI, United States.


A089 Influence of pre-diagnosis aspirin use on epithelial ovarian cancer tumor immune microenvironment markers: results from the Nurses’ Health Study (NHS) and NHSII. Melissa Merritt. The University of Sydney, New South Wales, Australia.

A090 An Inflammatory Adipose Microenvironment Promotes Ovarian Cancer Tumor Growth and Cisplatin Resistance. Michael Williams. Houston Methodist Research Institute, Houston, TX, United States.

A091 Crosstalk between tumour vasculature and ovarian cancer stem cells: the role of L1CAM. Micol Baronio. European Institute of Oncology IEO, Milan, MI, United States.

A092 Ovarian Tumor Organotypic Slices Cultures for functionAI drug screening (TOSCA). Rita Trozzi. Fondazione Policlinico Universitario A.Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy.
A093 Investigating alterations in metabolic profile of ovarian carcinoma associated mesenchymal stem cells. Roja Baruwal. University of Pittsburgh, Pittsburgh, PA, United States.

A094 CAF-derived MFAP5 enhances immune escape through up-regulating immune checkpoint mediator CD47 in ovarian cancer cells and CD8+ T cells. Sammy Ferri-Borgogno. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A095 Long-term ovarian cancer survivors: spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface. Sammy Ferri-Borgogno. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

A096 Blockade of LAIR1-collagen interaction enhances the therapeutic activity of BiTE-secreting T cells in ovarian cancer. Sarah Werner. Roswell Park Comprehensive Cancer Institute, Buffalo, NY, United States.

A097 Targeting ovarian cancer metastasis initiating cells induced by the microenvironment through ERK/EZH2/DNMT1 mediated miR-193b downregulation. Subramanyam Dasari. Indiana University School of Medicine – Bloomington, Bloomington, IN, United States.

A098 Microenvironment-regulated Matrix Gla Protein drives ovarian cancer stemness. Ugo Cavallaro. European Institute of Oncology IRCSS, Milano, Italy.

A099 Preliminary pharmacodynamic characterization in patients with platinum-resistant ovarian cancer treated with nemvaleukin in combination with pembrolizumab. Ulka Vaishampayan. Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, United States.

A100 Entinostat alters the M1/M2 ratio in ascites compared to tumors derived from an ID8 murine model of ovarian cancer. Vijayalaxmi Gupta. Washington University in St. Louis, St. Louis, MO, United States.

A101 A novel ovarian cancer organotypic tumor slice culture model. Violaine Pourcel. Université de Sherbrooke Faculty of Medicine, Sherbrooke, QC, Canada.

A102 ROR2/Wnt5a signaling regulates directional cell migration and early tumor cell invasion in ovarian cancer. Whitney Grither. Washington University, Saint Louis, MO, United States.

A103 Improved cell phenotyping of ovarian cancer tumor microenvironment. Ziqi Kang. Research Program in Systems Oncology, University of Helsinki, Finland, Helsinki, Finland.
A104 Untangling the effect of ascites in shaping high grade serous ovarian cancer progression. Pietro Lo Riso. IEO - European Institute of Oncology IRCCS, Milan, Italy.

A105 Associations between active cytomegalovirus infection and patient-reported quality of life, fatigue and cognitive functioning among ovarian cancer survivors. Rachel Vogel. University of Minnesota, Minneapolis, MN, United States.

A106 Characterizing the genomic and immunologic landscape of serous borderline tumors and low-grade serous ovarian cancer. Rahul Krishnan. University of Chicago, Chicago, IL, United States.


A108 Novel germline genetic variants in pseudogenes associated with overall survival in advanced stage ovarian cancer treated with carboplatin, paclitaxel, and bevacizumab: Results from the ROSiA trial. Salahaldin Alamleh. Temerty Faculty of Medicine - University of Toronto, Toronto, ON, Cananda.

A109 Targeting Methionine Metabolism Inhibits Ovarian Cancer Stem Cells. Shu Zhang. Indiana University Bloomington, Bloomington, IN, United States.


A111 Mechanisms underlying platinum-induced ovarian cancer stem cell plasticity. Tara Metcalfe. Indiana University-Bloomington, Bloomington, IN, United States.

A112 Extracellular vesicles derived from enriched ovarian cancer stem cell fractions promote stem like properties in the more vulnerable tumor cell populations. Venkatesh Pooladanda. Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, United States.

A113 Robust Establishment and Expansion of Multilineage Human Fallopian Tube Organoids in Serum-Free Medium. Victor Ho. STEMCELL Technologies, Vancouver, BC, Canada.

A114 DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review. Zoe Phan. Garvan Institute of Medical Research, Sydney, Australia.
Poster Session B (To be presented on October 6 from 7:30-9:00 p.m. ET)

Drug Discovery, Development, and Novel Pathways

B001 Comparative exploration of cultured spheroids and organoids as models to study epithelial ovarian cancer pathobiology. Emily Tomas. The University of Western Ontario, London, ON, Canada.

B002 Exploiting JAK/STAT signaling to inhibit highly advanced and resistant forms of ovarian cancer. Esther Rodman. Mayo Clinic, Rochester, MN, United States.

Epigenetics and Epitranscriptomics


B005 5-Hydroxymethylcytosine profiles in serum are a predictor of chemoresistance in high-grade serous ovarian cancer. Melanie Weigert. University of Chicago, Chicago, IL, United States.


B007 NAD+ metabolism drives PARPi resistance in ovarian cancer cells. Sridevi Challa. The University of Chicago, Chicago, IL, United States.

B008 Alternative PER2 (Period2) enhancer usage drives epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer (OC). Yi Chia Chiu. National Taiwan University, Taipei, Taiwan.


Drug Discovery, Development, and Novel Pathways

B010 Development of folate receptor alpha targeted FOXM1 inhibitors for ovarian cancer. Adam Karpf. University of Nebraska Medical Center, Omaha, NE, United States.


B014 Charting ovarian cancer dependencies with patient-derived organoids. Ashley Anderson. Broad Institute, Cambridge, MA, United States.

B015 CCDC80 as a novel cell intrinsic tumor suppressor protein in high grade serous ovarian cancer. Aya Saleh. Technion-Israel Institute of Technology and Rambam Health Care Campus, Haifa, Israel.

B016 Repurposing nelfinavir for re-sensitizing platinum-resistant high grade serous ovarian cancer cells. Benjamin Forgие. Experimental Pathology Unit, Department of Pathology, McGill University, Montreal, QC, Canada.

B017 Understanding the impact of transporter heterogeneity on the efficacy of PARP inhibitors. Carmen Ramirez Moncayo. Medical Research Council London Institute of Medical Sciences, London, United Kingdom.


B020 M1 macrophage engineered vesicles as ovarian cancer treatment in a mouse xenograft model. Connie Cao. University of Kentucky, Lexington, KY, United States.

B021 A phase 1 dose escalation study of lapatinib and paclitaxel in recurrent ovarian cancer. Connie Cao. University of Kentucky, Lexington, KY, United States.


B024 Maintenance therapy inhibition of ptk2 yields decreased disease in preclinical HRP/HRD models of recurrent HGSO. Dwayne Stupack. University of California, San Diego Moores Cancer Center, La Jolla, CA, United States.

B025 Hypoxia inducible factor 1 alpha regulates tumor progression in a human epithelial ovarian cancer model. María José España De Marco. Instituto de Biología y Medicina Experimental - CONICET, Ciudad Autónoma de Buenos Aires, Argentina.

B026 RPL8 amplification in high grade serous ovarian cancer is a frequent event and is correlated to outcome and response to treatment. Marianna Penzo. University of Bologna, Bologna, Italy.

B027 Screening of drug candidates to repurpose for high-grade serous ovarian cancer treatment. Marie Bay. Danish Cancer Institute, Copenhagen, Denmark.


B029 Targeting non-canonical function of TXNRD1 to overcome platinum resistance by eradicating ovarian cancer stem-like cells. Martina Towers. MD Anderson, Houston, TX, United States.

B030 PARP-1 inhibition results in ovarian and endometrial cancer cell death by disrupting the nucleolar localization of the RNA helicase DDX21 which is associated with decreased survival outcomes. Marwa Aljardali. UT Southwestern Medical Center, Dallas, TX, United States.

B031 The PLK1 inhibitor Volasertib as a treatment for HSF1 and MYC coamplified ovarian cancer. Matthew O'Malley. Indiana University School of Medicine, Bloomington, IN, United States.

B032 Probing the molecular crosstalk between ovarian cancer and omentum. Monica Haughan. University of Illinois at Chicago, Chicago, IL, United States.


B034 Targeting the HER family/Src pathways in ovarian cancer. Neil Conlon. Dublin City University, Dublin, Ireland.

B035 Cyclin E1 Positive Staining Is Frequent and Independent of Prior Platinum Treatment in High Grade Serous Ovarian Cancer. Olivier Harismendy. Zentalis Pharmaceuticals, San Diego, CA, United States.

American Association for Cancer Research Special Conference: OVARIAN CANCER | October 5-7, 2023| Westin Seaport Boston | Boston, MA
Early Detection and Prevention

B036 Spatial transcriptomics reveals stepwise biomolecular changes in ovarian cancer tumor microenvironments. AASA SHIMIZU. The University of Chicago, Chicago, IL, United States.


B038 Follicular fluid aids in cell adhesion, spreading and shows an age-dependent effect on DNA damage in fallopian tube epithelial cells. Amrita Salvi. University of Illinois, Chicago, Chicago, IL, United States.


B041 Modeling the malignant transformation of fallopian tube epithelium driven by extracellular vesicles cargos in an organ-on-chip microphysiological system. Didi Zha. University of Illinois at Chicago, CHICAGO, IL, United States.

B042 Feasibility of an Electronic Medical Records Based Ovarian Cancer Symptom Screening Patient Questionnaire. Kian Behbakht. The University of Colorado, Aurora, CO, United States.


B044 Serum miRNA expression in ovarian cancer patients is independent of histological subtype and FIGO stage. Laura Wollborn. Brigham and Women's Hospital, Boston, MA, United States.


B048 Evaluating the impact of pulmonary diseases on the use of microRNAs as biomarkers for early detection of ovarian cancer. Monica Moore. Howard University, Washington, DC, United States.


B051 Genome-wide association studies of 26,187 women without ovarian cancer identifies 12 genetic loci of blood CA125. Naoko Sasamoto. Brigham and Women's Hospital, Boston, MA, United States.

B052 Ovarian cancer risk prediction: A systematic assessment of the state of the art and development of a new model. Nicolas Wentzensen. National Cancer Institute, Rockville, MD, United States.

Rare Ovarian Tumors

B053 Lipid metabolism and lipidomics of ovarian clear cell carcinoma: A comprehensive analysis. Agnes Bilecz. University of Chicago, Chicago, IL, United States.


B055 Identifying compounds to promote apoptotic cell death in clear cell ovarian cancer. Elizabeth Stover. Dana-Farber Cancer Institute, Boston, MA, United States.

B056 The Unconfounded Effect of Bevacizumab on Advanced Ovarian Clear Cell Carcinoma: A Systematic Review, Traditional Meta-Analysis, and Network Meta-Analysis. Fisher Huang. National Taiwan University Hospital, Yunlin Branch, Yunlin county, Taiwan.

B057 Oncogenic Foxl2 directs enhancer reprogramming and changes in 3D genome structure in ovarian granulosa cell tumors. Veena K. Vuttaradhi. University of Texas MD Anderson Cancer Center, HOUSTON, TX, United States.

B058 Targeting Mediator Kinase CDK8/19 potentiates chemotherapeutic responses, reverses tumor growth, and prolongs survival from ovarian clear cell carcinoma. Wade Barton. The University of Alabama, Birmingham, AL, United States.
B059 *A patient-derived xenograft (PDX) orthotopic mouse model of rare gynecologic mesonephric-like adenocarcinoma as a platform of personalized medicine.* Yasuto Kinose. Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Tumor Microenvironment and Immune Oncology II

B060 *Spatial landscape of cell cycle dynamics post-neoadjuvant chemotherapy in high-grade serous ovarian carcinoma.* Ada Junquera. University of Helsinki, Helsinki, Finland.

B061 *Multiparametric;single-cell characterization of the immune tumor microenvironment of HGSC tumors before and after neoadjuvant chemotherapy.* Antonio Delgado-Gonzalez. Stanford University, Stanford, CA, United States.

B062 *Role of cancer associated fibroblasts in ovarian cancer relapse.* Argha Ghosh. Indiana University School of Medicine - Bloomington, Bloomington, IN, United States.

B063 *Vascular senescence associated cell migration inducing hyaluronidase-1 production promotes ovarian cancer migration and tumorigenesis.* Asha Kumari. Department of Pathology and O'Neal Comprehensive Cancer Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.

B064 *Reconstructing the metastatic tumour microenvironment of high grade serous ovarian cancer using human;multicellular in vitro models.* Beatrice Malacrida. Queen Mary University of London, London, United Kingdom.

B065 *Dual targeting of IDO1/TDO2 inhibits tumor progression and attenuates the immune suppressive tumor microenvironment.* Benjamin Bitler. The University of Colorado, Denver, CO, United States.

B066 *Elucidating the impact of ascites on high grade serous ovarian cancer through in vitro multi-model characterization.* Bianca Barzaghi. European Institute of Oncology, Milan, MI, United States.

B067 *Omentin: A novel immune modulator in the pro-inflammatory omental microenvironment of high-grade serous ovarian cancer.* Chi Lam Au Yeung. The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B068 *FOXM1 mediates the crosstalk between tumor microenvironment and ovarian cancer stem cells as revealed by patient-derived organotypic models.* Chiara Battistini. European Institute of Oncology IRCCS, Milan, Italy.

B069 *Bone marrow-derived adipocytes promote ovarian cancer progression and metastasis.* Courtney Bailey. University of Colorado, Aurora, CO, United States.
B070 Logic-gated CAR T cell product AB-1015 response to ovarian cancer models with heterogeneous levels of ALPG/P antigen. Dina Polyak. ArsenalBio, South San Francisco, CA, United States.

B071 Mesothelial cell motility and contractility promote ovarian cancer metastatic potential through a PKA-dependent mechanism. Dorota Jazwinska. University of Pittsburgh, Pittsburgh, PA, United States.

B072 Claudin-4 modulates autophagy via cell-cell junctions as a cellular protective mechanism before genomic instability in ovarian cancer. Fabian Villagomez. University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

B073 A spatially resolved single-cell tumor microenvironment of clinicomolecular subtypes of high-grade serous ovarian cancer. Fernando Perez-Villatoro. University of Helsinki, Faculty of Medicine, Research program in systems oncology., Helsinki, Finland.

B074 Proteogenomic Analysis of Enriched Tumor Epithelium Identifies Prognostic Signatures and an Increased Dependency of Homologous Recombination Proficient Cells on BMI1 in High Grade Serous Ovarian Cancer. George Maxwell. Inova Health System, Falls Church, VA, United States.

B075 Spatial genomics identifies cancer cell cytokines regulating ovarian cancer immunity. Gurkan Mollaoglu. Icahn School of Medicine at Mount Sinai, New York, NY, United States.

B076 Targeting Cancer Glycomes Sensitizes Ovarian Tumors to Immunotherapy. Hao Nie. MD Anderson Cancer Center, Houston, TX, United States.

B077 Spatial patterns of immune cell states are associated with poor response to neoadjuvant chemotherapy in high-grade serous ovarian cancer. Iga Niemiec. University of Helsinki, Helsinki, Finland.

B078 Insulin-like growth factor signaling contributes to omental preadipocyte-mediated tumorigenesis in ovarian cancer by regulating expression of extracellular matrix genes. Jennifer Waters. San Diego State University, San Diego, CA, United States.


B081 Type-I interferon (IFN-I) signaling following aurora kinase A (AURKA) inhibition is modulated by tumor p53 status. Karen McLean. Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.


B084 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer. Kristin Anderson. University of Virginia, Charlottesville, VA, United States.

B085 Carcinoma-associated mesenchymal stem cells promote high-grade serous ovarian cancer metastasis and drive tumor heterogeneity at the metastatic site through direct mitochondrial transfer. Leonard Frisbie. University of Pittsburgh, Pittsburgh, PA, United States.


B087 Targeting myeloid derived suppressor cell migration decreases tumor progression in a murine model of ovarian cancer. Nicole Marjon. University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

B088 Elucidating the role of amphiregulin in the ovarian tumor immune microenvironment. Nicole James. Women and Infants Hospital of Rhode Island/ Warren Alpert Medical School of Brown University, Providence, RI, United States.

B089 Intratumoral expression analysis of mast cells in high grade serous ovarian cancer. Nicole James. Women and Infants Hospital of Rhode Island / Warren Alpert Medical School of Brown University, Providence, RI, United States.

B090 Gut microbial suppression of Epithelial Ovarian Cancer and attenuation of chemoresistance. Opportunity for probiotics in patient care to improve survival. Ofer Reizes. Cleveland Clinic, Cleveland, OH, United States.

B091 Mechanisms underlying the omental support of ovarian cancer peritoneal metastasis. Rachel Mintz. Washington University in St. Louis, St. Louis, MO, United States.


B094 A combined RAD51 and phosphorylated replication protein assay predict response to platinum chemotherapy in high-grade serous ovarian cancer. Amanda Compadre. Washington University in St Louis, St Louis, MO, United States.

B095 Tenascin C promotes ovarian cancer stem cells interactions with the niche. Amber Rogers. Indiana University School of Medicine, Indianapolis, IN, United States.


B097 Image analysis-guided spatial transcriptomics improves recognition of biological features important for outcome in high grade serous carcinoma. Anna Laury. University of Helsinki, Helsinki, Finland.


B100 Perfluoroalkyl substances (PFAS) induce platinum resistance in ovarian cancer through altering mitochondrial function. Brittany Rickard. University of North Carolina, Chapel Hill, NC, United States.


B102 Mutational and copy number-based ctDNA profiles mirror High-Grade Serous Cancer tumors and enable detection of genetic changes appearing at recurrence. Giovanni Marchi. University of Helsinki, Helsinki, Finland.

B103 The impact of ULK1 deficiency on autophagy, cell viability, and tumour progression in experimental models of ovarian cancer metastasis. Jack Webb. Western University, London, ON, United Kingdom.
B104 Establishing patient derived organoids for high-grade serous ovarian cancer as representative models for pre-clinical research. James Clark. Imperial College London, London, United Kingdom.


B106 A minimal driver pair for a spontaneous high-grade serous ovarian cancer mouse model: Myc and p53-R270H. Joe Delaney. Medical University of South Carolina, Charleston, SC, United States.

B107 Elucidating the Influence of Long-Chain Fatty Acids on Ovarian Cancer Progression. Jumpei Ogura. Kyoto University, Kyoto, Japan.


B110 Bridging the academic-industry gap to promote health equity: RE-AIMing the implementation of the AKRIVIS GDTM test go-to-market strategy. Margo Harrison. AOADx, Boulder, CO, United States.


B112 A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory ovarian cancer and transcriptionally addicted relapsed or refractory solid tumors. Miguel Villalona-Calero. City of Hope, Duarte, CA, United States.

B113 Associations between risk factors and epithelial ovarian cancer survival by racial and ethnic group: an analysis from the Ovarian Cancer Association Consortium. Nicola Meagher. The Daffodil Centre, Sydney, NSW, Australia.

B114 Effect of spatial and temporal Inter-tumoral heterogeneity on Homologous Recombination Deficiency scores in High Grade Serous Ovarian Cancer. Paula Cunnea. Imperial College London, London, United Kingdom.